Literature DB >> 22674051

Neuroprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on spinal cord injury.

Daisuke Tsuchikawa1, Tomoya Nakamachi, Masashi Tsuchida, Yoshihiro Wada, Motohide Hori, Jozsef Farkas, Akira Yoshikawa, Nobuyuki Kagami, Nori Imai, Norihito Shintani, Hitoshi Hashimoto, Takashi Atsumi, Seiji Shioda.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuroprotective peptide expressed in the central nervous system. To date, changes in the expression and effect of endogenous PACAP have not been clarified with respect to spinal cord injury (SCI). The aim of this study was to elucidate the expression pattern and function of endogenous PACAP on the contusion model of SCI using heterozygous PACAP knockout (PACAP(+/-)) and wild-type mice. Real-time polymerase chain reaction methods revealed that the level of PACAP mRNA increased gradually for 14 days after SCI and that PAC1R mRNA levels also increased for 7 days compared with intact control mice. PACAP and PAC1R immunoreactivities colabeled with a neuronal marker in the intact spinal cord. Seven days after SCI, PAC1R immunoreactivity was additionally co-expressed with an astrocyte marker. Wild-type mice gradually recovered motor function after 14 days, but PACAP(+/-) mice showed significantly impaired recovery from 3 days compared with wild-type mice. The injury volume at day 7 in PACAP(+/-) mice, and the number of single-stranded DNA-immunopositive cells as a marker of neuronal cell death at day 3 were significantly higher than values measured in wild-type mice. These data suggest that endogenous PACAP is upregulated by SCI and has a neuroprotective effect on the damaged spinal cord.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674051     DOI: 10.1007/s12031-012-9817-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  48 in total

1.  Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains.

Authors:  D Michele Basso; Lesley C Fisher; Aileen J Anderson; Lyn B Jakeman; Dana M McTigue; Phillip G Popovich
Journal:  J Neurotrauma       Date:  2006-05       Impact factor: 5.269

2.  Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult.

Authors:  David Vaudry; Carol Hamelink; Ruslan Damadzic; Robert L Eskay; Bruno Gonzalez; Lee E Eiden
Journal:  Peptides       Date:  2005-07-11       Impact factor: 3.750

Review 3.  Current status and prospective application of stem cell-based therapies for spinal cord injury.

Authors:  Anjan Kumar Das; Renjitha Gopurappilly; Ishwar Parhar
Journal:  Curr Stem Cell Res Ther       Date:  2011-06       Impact factor: 3.828

4.  Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo.

Authors:  K Szabadfi; T Atlasz; P Kiss; B Danyadi; A Tamas; Zs Helyes; H Hashimoto; N Shintani; A Baba; G Toth; R Gabriel; D Reglodi
Journal:  Neurotox Res       Date:  2011-06-30       Impact factor: 3.911

5.  The axotomy-induced neuropeptides galanin and pituitary adenylate cyclase-activating peptide promote axonal sprouting of primary afferent and cranial motor neurones.

Authors:  Victor Suarez; Orlando Guntinas-Lichius; Michael Streppel; Shota Ingorokva; Maria Grosheva; Wolfram F Neiss; Doychin N Angelov; Lars Klimaschewski
Journal:  Eur J Neurosci       Date:  2006-09       Impact factor: 3.386

6.  Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury.

Authors:  Wen-Hsin Chen; Shun-Fen Tzeng
Journal:  Neurosci Lett       Date:  2005 Aug 12-19       Impact factor: 3.046

7.  Pituitary adenylate cyclase-activating polypeptide protects astroglial cells against oxidative stress-induced apoptosis.

Authors:  Olfa Masmoudi-Kouki; Salma Douiri; Yosra Hamdi; Hadhémi Kaddour; Saima Bahdoudi; David Vaudry; Magali Basille; Jérôme Leprince; Alain Fournier; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri
Journal:  J Neurochem       Date:  2011-03-15       Impact factor: 5.372

8.  Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury.

Authors:  Orsolya Farkas; Andrea Tamás; Andrea Zsombok; Dóra Reglodi; József Pál; Andras Büki; István Lengvári; John T Povlishock; Tamás Dóczi
Journal:  Regul Pept       Date:  2004-12-15

9.  Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage.

Authors:  Ralf Stumm; Angela Kolodziej; Vincent Prinz; Matthias Endres; Dai-Fei Wu; Volker Höllt
Journal:  J Neurochem       Date:  2007-09-14       Impact factor: 5.372

Review 10.  PACAP is implicated in the stress axes.

Authors:  Hitoshi Hashimoto; Norihito Shintani; Mamoru Tanida; Atsuko Hayata; Ryota Hashimoto; Akemichi Baba
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

View more
  19 in total

1.  PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglödi; Yousef Tizabi
Journal:  J Mol Neurosci       Date:  2013-04-28       Impact factor: 3.444

2.  PACAP enhances barrier properties of cerebral microvessels.

Authors:  Imola Wilhelm; Csilla Fazakas; Andrea Tamás; Gábor Tóth; Dóra Reglődi; István A Krizbai
Journal:  J Mol Neurosci       Date:  2014-03-11       Impact factor: 3.444

3.  PACAP38 suppresses cortical damage in mice with traumatic brain injury by enhancing antioxidant activity.

Authors:  Kazuyuki Miyamoto; Tomomi Tsumuraya; Hirokazu Ohtaki; Kenji Dohi; Kazue Satoh; Zhifang Xu; Sachiko Tanaka; Norimitsu Murai; Jun Watanabe; Koichi Sugiyama; Tohru Aruga; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2014-06-08       Impact factor: 3.444

4.  Examination of calcium-binding protein expression in the inner ear of wild-type, heterozygous and homozygous pituitary adenylate cyclase-activating polypeptide (PACAP)-knockout mice in kanamycin-induced ototoxicity.

Authors:  A Nemeth; K Szabadfi; B Fulop; D Reglodi; P Kiss; J Farkas; B Szalontai; R Gabriel; H Hashimoto; A Tamas
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

5.  Early Neurobehavioral Development of Mice Lacking Endogenous PACAP.

Authors:  Jozsef Farkas; Balazs Sandor; Andrea Tamas; Peter Kiss; Hitoshi Hashimoto; Andras D Nagy; Balazs D Fulop; Tamas Juhasz; Sridharan Manavalan; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2017-02-06       Impact factor: 3.444

6.  Comparison of expression and proliferative effect of pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors on human astrocytoma cell lines.

Authors:  Tomoya Nakamachi; Kouichi Sugiyama; Jun Watanabe; Nori Imai; Nobuyuki Kagami; Motohide Hori; Satoru Arata; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2014-08-06       Impact factor: 3.444

7.  ClC-2-like Chloride Current Alterations in a Cell Model of Spinal and Bulbar Muscular Atrophy, a Polyglutamine Disease.

Authors:  Vladimir A Martínez-Rojas; Aura M Jiménez-Garduño; Daniela Michelatti; Laura Tosatto; Marta Marchioretto; Daniele Arosio; Manuela Basso; Maria Pennuto; Carlo Musio
Journal:  J Mol Neurosci       Date:  2020-08-28       Impact factor: 3.444

Review 8.  PACAP deficiency as a model of aging.

Authors:  D Reglodi; T Atlasz; E Szabo; A Jungling; A Tamas; T Juhasz; B D Fulop; A Bardosi
Journal:  Geroscience       Date:  2018-10-22       Impact factor: 7.713

9.  PACAP stimulates functional recovery after spinal cord injury through axonal regeneration.

Authors:  Masashi Tsuchida; Tomoya Nakamachi; Kouichi Sugiyama; Daisuke Tsuchikawa; Jun Watanabe; Motohide Hori; Akira Yoshikawa; Nori Imai; Nobuyuki Kagami; Attila Matkovits; Takashi Atsumi; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2014-07-31       Impact factor: 3.444

Review 10.  VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair.

Authors:  J A Waschek
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.